CIPRO I.V. - LIQ 10MG/ML LIQUID

Nazione: Canada

Lingua: inglese

Fonte: Health Canada

Principio attivo:

CIPROFLOXACIN (CIPROFLOXACIN LACTATE)

Commercializzato da:

BAYER INC

Codice ATC:

J01MA02

INN (Nome Internazionale):

CIPROFLOXACIN

Dosaggio:

10MG

Forma farmaceutica:

LIQUID

Composizione:

CIPROFLOXACIN (CIPROFLOXACIN LACTATE) 10MG

Via di somministrazione:

INTRAVENOUS

Confezione:

40 ML

Tipo di ricetta:

Prescription

Area terapeutica:

QUINOLONES

Dettagli prodotto:

Active ingredient group (AIG) number: 0123207003; AHFS:

Stato dell'autorizzazione:

CANCELLED POST MARKET

Data dell'autorizzazione:

2005-07-27

Scheda tecnica

© 2008, Bayer Inc.
® CIPRO is a registered trademard, used under license by Bayer Inc.
PRODUCT MONOGRAPH
CIPRO
®
(CIPROFLOXACIN HYDROCHLORIDE TABLETS)
250 MG, 500 MG, 750 MG
U.S.P.
CIPRO
® I.V.
(CIPROFLOXACIN INJECTION)
10 MG/ML IN WATER FOR INJECTION
BAYER STANDARD
CIPRO
® I.V. MINIBAGS
(CIPROFLOXACIN INJECTION)
2 MG/ML IN 5% DEXTROSE
BAYER STANDARD
CIPRO
® ORAL SUSPENSION
(CIPROFLOXACIN ORAL SUSPENSION)
10G/100 ML
BAYER STANDARD
ANTIBACTERIAL AGENT
BAYER INC.
DATE OF REVISION:
77 BELFIELD ROAD
JUNE 5, 2008
TORONTO, ONTARIO
M9W 1G6
CANADA
WWW.BAYER.CA
CONTROL NUMBER:
120682
2
PRODUCT MONOGRAPH
CIPRO
®
(Ciprofloxacin Hydrochloride Tablets)
250 mg, 500 mg, 750 mg
U.S.P.
CIPRO
®
I.V.
(Ciprofloxacin Injection)
10 mg/mL in Water for Injection
Bayer Standard
CIPRO
®
I.V. MINIBAGS
(Ciprofloxacin Injection)
2 mg/mL in 5% Dextrose
Bayer Standard
CIPRO
®
ORAL SUSPENSION
(Ciprofloxacin Oral Suspension)
10 g/100 mL
Bayer Standard
THERAPEUTIC CLASSIFICATION
Antibacterial Agent
3
ACTION AND CLINICAL PHARMACOLOGY
ACTION
Ciprofloxacin, a synthetic fluoroquinolone, has
_in vitro _
activity against a wide range of gram-
negative and gram-positive microorganisms. Its bactericidal action is
achieved through inhibition
of topoisomerase II (DNA gyrase) and topoisomerase IV (both Type II
topoisomerases), which are
required for bacterial DNA replication, transcription, repair, and
recombination.
Ciprofloxacin retained some of its bactericidal activity after
inhibition of RNA and protein synthesis
by rifampin and chloramphenicol, respectively. These observations
suggest ciprofloxacin may
possess two bactericidal mechanisms, one mechanism resulting from the
inhibition of DNA gyrase
and a second mechanism which may be independent of RNA and protein
synthesis.
The mechanism of action of fluoroquinolones, including ciprofloxacin,
is different from that of
penicillins,
cephalosporins,
aminoglycosides,
macrolides,
and
tetracyclines.
Therefore,
microorganisms resistant to these classes of drugs may be susceptible
to ciprofloxacin. Co